Earnings Surprises

We delivered another strong quarter, with solid execution across the business led by our market-leading biopreservation media franchise.

Cronos delivered a record second quarter by organically achieving record net revenue, record gross profit and record Adjusted EBITDA, while also reducing our share count. Cronos Israel delivered its tenth consecutive quarter of record net revenue, continuing to secure PEACE NATURALS as the leading cannabis brand in the country. Outside of Israel, our international business also delivered a record net revenue quarter, led by momentum in Germany. In Canada, the Spinach brand continued to gain sign

Our second quarter results exceeded our expectations, demonstrating meaningful progress across agilon's strategic initiatives and reinforcing our confidence in the strength of our Total Care Model.

STAAR is off to a strong start in 2026, as reflected in our first quarter financial results. We have made meaningful advancements against our core objectives of Revenue Growth and Profit Expansion.

We started the year strong, focused on delivering for our clients with excellence and making advances in our strategic journey back to growth and margin expansion.

Our first-quarter performance demonstrates that Alignment continues to grow with discipline. We expanded our profitability by executing across sales, clinical operations and cost management, even as the Medicare Advantage environment continues to change.

We are very pleased with how the AMN team executed for our healthcare professionals and clients in the second quarter. Our strong performance produced year-over-year revenue growth in our travel nurse, international nurse, allied, schools, and search solutions.

We delivered a solid start to 2026, with first quarter revenue up 25% year-over-year and adjusted EBITDA of $6.2 million. Healthy demand for our biopreservation media and growth across our broader product portfolio reinforces our market leading position.

We delivered an exceptional quarter to begin the year, highlighted by strong revenue growth of 21%, net income growth of $13.5 million, and Adjusted EBITDA growth of 48%.

We entered 2026 with clear priorities—stabilizing the business, restoring growth, maintaining financial strength, and advancing a pipeline that we believe can define Sarepta’s next era.

Our team delivered another quarter of record growth, driven by continued momentum in our Precision Medicine Testing Services and Patient and Digital Solutions businesses.

Oscar delivered record profitability in the first half of the year and we are raising our full-year 2026 guidance. Our superior operating performance and execution against the fundamentals of our strategy are accelerating the individual market.

In the second quarter of 2026, we delivered 9% constant currency revenue growth and 7% adjusted EBITDA growth, reflecting continued execution of our strategy to drive long-term, profitable growth through an expanding and clinically differentiated product portfolio.

2026 is a defining year for Hims & Hers. We're not just growing, we're pulling away from the field on our path to becoming the world's largest consumer health platform.

Our results for Q1 2026 reflected the early yet measurable progress generated by our refined global business model which we adopted in mid-2025.

We delivered a solid third quarter, reflecting continued improvement in operating execution and financial performance.

Our second quarter results fell short of our expectations, reflecting both execution gaps and a more cautious demand environment, particularly in North America.

This was a record quarter, with approximately 59,200 clinical cases, up more than 12% sequentially, reflecting sustained demand and the payoff from investments in our commercial engine.